The article discusses the expanding role of Ozempic and similar drugs, particularly focusing on their potential to treat advanced stages of fatty liver disease. Recent research indicates that semaglutide, the active ingredient, shows the ability to not only stop the disease's progression but also potentially reverse it. Two-thirds of trial participants experienced reduced liver inflammation, and 37% showed improvement in fibrosis. This discovery enhances the options available for treating a serious condition affecting one in three adults, suggesting a wider therapeutic potential for GLP-1 receptor agonists beyond obesity and diabetes management.
According to new research published Wednesday in The New England Journal of Medicine, semaglutide not only halts the progression of fatty liver disease but may even reverse it.
The researchers emphasize that this discovery opens the door to a new therapeutic landscape for a serious condition that, until now, lacked a substantial pharmacological arsenal.
With these drugs, visceral fat is reduced, but we have receptors for these molecules in almost every organ, and they will also have an effect.
These groundbreaking drugs help patients lose around 15% of their body weight and have transformed the treatment of diabetes and obesity.
Collection
[
|
...
]